Corpus Intelligence IC Memo — WOODHULL HOSPITAL CENTER 2026-04-26 05:02 UTC
IC Memo — WOODHULL HOSPITAL CENTER
Investment Committee Memorandum | NY | 238 beds | Grade C | EBITDA uplift $39.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

WOODHULL HOSPITAL CENTER

CCN 330396 | KINGS, NY | 238 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

WOODHULL HOSPITAL CENTER is a 238-bed suburban community hospital in KINGS, NY with $529.9M in net patient revenue and a -8.6% operating margin. The hospital serves a payer mix of 9.8% Medicare, 19.4% Medicaid, and 70.9% commercial.

Thesis: Undervalued. Our ML models identify $39.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -8.6% to -1.3% (+736bps).

Net Revenue HCRIS$529.9M
Current EBITDA COMPUTED$-45.8M
Operating Margin COMPUTED-8.6%
Occupancy HCRIS51.3%
Revenue / Bed COMPUTED$2.2M
Net-to-Gross HCRIS51.5%
Distress Probability ML52.2%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
97
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -8.6% places it above the state median. Among 97 size-comparable peers (119-476 beds), the median margin is -17.8%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (119-476), prioritizing same-state peers. 97 hospitals in the comp set.

HospitalStateBedsRevenueMargin
WOODHULL HOSPITAL CENTER (Target)NY238$529.9M-8.6%
LENOX HILL HOSPITALNY415$1.32B-35.1%
JACOBI MEDICAL CENTERNY440$1.14B-16.8%
HOSPITAL FOR SPECIAL SURGERYNY200$1.12B-29.3%
ROCHESTER GENERAL HOSPITALNY470$1.05B-27.9%
NYC HEALTH+HOSPITAL/KINGS COUNNY381$1.03B-15.0%
NEWYORK-PRESBYTERIAN/QUEENSNY476$890.1M-50.0%
ST. FRANCIS HOSPITALNY364$889.3M2.0%
WHITE PLAINS HOSPITALNY292$884.7M8.7%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $39.0M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$11.1M+210bp18mo
Cost to Collect4.5%2.5%$10.6M+200bp12mo
Denial Rate Reduction12.0%6.5%$10.5M+198bp12mo
A/R Days Reduction5200.0%3800.0%$6.4M+122bp9mo
Clean Claim Rate88.0%96.0%$339K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$11.1M
Cost to Collect
$10.6M
Denial Rate Reduction
$10.5M
A/R Days Reduction
$6.4M
Clean Claim Rate
$339K
Total EBITDA Uplift$39.0M
Current EBITDA$-45.8M
+ RCM Uplift+$39.0M
Pro Forma EBITDA$-6.8M
Current Margin-8.6%
Pro Forma Margin-1.3%
WC Released (1x)$20.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-70.5M$87.7M0.00x-100.0%
Base (11x exit)10.0x11.0x$-70.5M$73.6M0.00x-100.0%
Bull Case9.0x11.0x$-63.5M$179.4M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-63.5M$177.0M0.00x-100.0%
Bear Case11.0x10.0x$-77.6M$-84.4M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-77.6M$-118.0M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 52.2% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 97 hospitals with 119-476 beds
  • Same-state prioritization (n=98)
  • Comp margins: P25=-27.9% / P50=-17.8% / P75=-9.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.